rock (RHHBY) unveiled positive results for a rival to Therapeutic TG‘ (TGTX) one-hour infusion for patients with multiple sclerosis, and the stock of TGTX collapsed.
Swiss pharmaceutical company Roche has tested an injection under the skin of its flagship treatment for multiple sclerosis, Ocrevus. The 10-minute twice-a-year injection has proven to be no inferior to the first iteration of Ocrevus, a six-monthly infusion that takes two and a half hours each time to administer.
Roche says it wants to expand Ocrevus to countries where there are fewer infusion centers. But investors hammered TGTX stock. TG Therapeutics won approval in December for a one-hour biannual infusion to treat multiple sclerosis called Briumvi.
In premarket trading on the stock market today, TGTX stock plunged 8.5% around 11:30 p.m. The Roche action did not move.
TG Therapeutics stock has the best possible relative strength rating of 99. This means that TGTX stock ranks in the top 1% of all stocks when it comes to 12-month performance, according to IBD Digital.
Follow Allison Gatlin on Twitter at @IBD_AGatlin.
YOU MIGHT ALSO LIKE:
InMode, a 1% higher profit machine, bursts after a strong pre-announcement – but there is a caveat
Recursion catapults 78% on Nvidia’s AI investment in drug development
See stocks on the leader list near a buy point
Best Growth Stocks to Buy and Watch: See IBD Stock List Updates
Watch the IBD Investment Strategies Show for actionable market insights